Neoadjuvant Chemotherapy for High-risk Localized Upper Tract Urothelial Carcinoma: Final Long-term Outcomes from a Phase 2 Clinical Trial and an Expanded Cohort.
Publication/Presentation Date
9-25-2025
Abstract
We previously reported results from a prospective, multicenter, phase 2 trial that demonstrated a pathologic response rate (
ISSN
1873-7560
Published In/Presented At
Jayalath, V. H., Assel, M., Iyer, G., Niglio, S., Bochner, B. H., Dalbagni, G., Donat, S. M., Herr, H. W., Cha, E. K., Donahue, T. F., Pietzak, E. J., Hakimi, A. A., Kim, K., Al-Ahmadie, H. A., Vargas, H. A., Ghafoor, S., Benfante, N. E., Rodriguez, D. V., Meyerson, A. R., Meraney, A. M., … Coleman, J. A. (2025). Neoadjuvant Chemotherapy for High-risk Localized Upper Tract Urothelial Carcinoma: Final Long-term Outcomes from a Phase 2 Clinical Trial and an Expanded Cohort. European urology, S0302-2838(25)00503-2. Advance online publication. https://doi.org/10.1016/j.eururo.2025.08.012
Disciplines
Medicine and Health Sciences
PubMedID
41006098
Department(s)
Department of Medicine, Hematology-Medical Oncology Division, Department of Surgery
Document Type
Article